In general, DPP-4 inhibitors did not show an increased risk of CV death, nonfatal myocardial infarction, or nonfatal stroke when compared to placebo, although saxagliptin had an association with an increased rate of hospitalization for heart failure [96]. Here, DPP4 is linked to Stroke.